JP2024504542A - Ｂｃｌ－２阻害剤としてのスルホニルベンズアミド誘導体 - Google Patents

Ｂｃｌ－２阻害剤としてのスルホニルベンズアミド誘導体 Download PDF

Info

Publication number
JP2024504542A
JP2024504542A JP2023527410A JP2023527410A JP2024504542A JP 2024504542 A JP2024504542 A JP 2024504542A JP 2023527410 A JP2023527410 A JP 2023527410A JP 2023527410 A JP2023527410 A JP 2023527410A JP 2024504542 A JP2024504542 A JP 2024504542A
Authority
JP
Japan
Prior art keywords
cancer
methyl
mmol
compound
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504542A5 (https=
Inventor
トンポー リー
チエンヨン チェン
ファン リウ
ハオ チェン
シエンチャン チャー
Original Assignee
アセンテージ ファーマ（スーチョウ）カンパニー，リミティド
アセンテージ ファーマ グループ コーポレイション リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アセンテージ ファーマ（スーチョウ）カンパニー，リミティド, アセンテージ ファーマ グループ コーポレイション リミティド filed Critical アセンテージ ファーマ（スーチョウ）カンパニー，リミティド
Publication of JP2024504542A publication Critical patent/JP2024504542A/ja
Publication of JP2024504542A5 publication Critical patent/JP2024504542A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023527410A 2021-02-01 2022-01-30 Ｂｃｌ－２阻害剤としてのスルホニルベンズアミド誘導体 Pending JP2024504542A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021074709 2021-02-01
CNPCT/CN2021/074709 2021-02-01
PCT/CN2022/075239 WO2022161496A1 (en) 2021-02-01 2022-01-30 Sulfonyl benzamide derivatives as bcl-2 inhibitors

Publications (2)

Publication Number Publication Date
JP2024504542A true JP2024504542A (ja) 2024-02-01
JP2024504542A5 JP2024504542A5 (https=) 2024-12-13

Family

ID=82562087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527410A Pending JP2024504542A (ja) 2021-02-01 2022-01-30 Ｂｃｌ－２阻害剤としてのスルホニルベンズアミド誘導体

Country Status (5)

Country Link
US (1) US12577245B2 (https=)
EP (1) EP4298098A4 (https=)
JP (1) JP2024504542A (https=)
CN (1) CN114835704B (https=)
WO (1) WO2022161496A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024032776A1 (en) * 2022-08-12 2024-02-15 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511530A (ja) * 2003-11-13 2007-05-10 アボット・ラボラトリーズ Ｎ−アシルスルホンアミド系アポトーシス促進剤
JP2012511020A (ja) * 2008-12-05 2012-05-17 アボット・ラボラトリーズ 癌および免疫疾患の治療のためのｂｃｌ−２−選択的アポトーシス誘発剤としてのスルホンアミド誘導体
JP2013523636A (ja) * 2010-03-25 2013-06-17 アッヴィ・インコーポレイテッド 癌ならびに免疫および自己免疫疾患の治療のためのアポトーシス誘導物質
JP2016517406A (ja) * 2013-03-14 2016-06-16 アッヴィ・インコーポレイテッド 癌並びに免疫疾患及び自己免疫疾患の治療用としてのアポトーシス誘導剤
CN108658983A (zh) * 2017-06-26 2018-10-16 深圳市塔吉瑞生物医药有限公司 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
WO2019185025A1 (zh) * 2018-03-30 2019-10-03 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
WO2020088442A1 (zh) * 2018-10-29 2020-05-07 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
WO2020238785A1 (zh) * 2019-05-24 2020-12-03 正大天晴药业集团股份有限公司 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US10829488B2 (en) * 2016-08-05 2020-11-10 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
EP3565815B1 (en) * 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
CN113444078B (zh) * 2020-03-25 2023-07-07 中国科学院上海有机化学研究所 抗凋亡蛋白Bcl-2抑制剂及其制备方法和应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007511530A (ja) * 2003-11-13 2007-05-10 アボット・ラボラトリーズ Ｎ−アシルスルホンアミド系アポトーシス促進剤
JP2012511020A (ja) * 2008-12-05 2012-05-17 アボット・ラボラトリーズ 癌および免疫疾患の治療のためのｂｃｌ−２−選択的アポトーシス誘発剤としてのスルホンアミド誘導体
JP2013523636A (ja) * 2010-03-25 2013-06-17 アッヴィ・インコーポレイテッド 癌ならびに免疫および自己免疫疾患の治療のためのアポトーシス誘導物質
JP2016517406A (ja) * 2013-03-14 2016-06-16 アッヴィ・インコーポレイテッド 癌並びに免疫疾患及び自己免疫疾患の治療用としてのアポトーシス誘導剤
CN108658983A (zh) * 2017-06-26 2018-10-16 深圳市塔吉瑞生物医药有限公司 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
WO2019185025A1 (zh) * 2018-03-30 2019-10-03 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
WO2020088442A1 (zh) * 2018-10-29 2020-05-07 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
WO2020238785A1 (zh) * 2019-05-24 2020-12-03 正大天晴药业集团股份有限公司 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂

Also Published As

Publication number Publication date
US20240166644A1 (en) 2024-05-23
US12577245B2 (en) 2026-03-17
CN114835704B (zh) 2023-10-27
EP4298098A1 (en) 2024-01-03
EP4298098A4 (en) 2025-06-25
WO2022161496A1 (en) 2022-08-04
CN114835704A (zh) 2022-08-02

Similar Documents

Publication Publication Date Title
KR102429704B1 (ko) Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
JP7352284B2 (ja) ＬＳＤ－１インヒビターとしてのピロロ〔２，３－ｃ〕ピリジン及び関連類似体
KR20180132125A (ko) Mdm2 단백질 분해제
TW202003465A (zh) 作為共價menin抑制劑之六氫吡啶化合物
JP2016519660A (ja) ブロモドメイン阻害剤としてのオキサゾロ［５，４−ｃ］キノリン−２−オン化合物
JP2024504542A (ja) Ｂｃｌ－２阻害剤としてのスルホニルベンズアミド誘導体
CN103459396B (zh) 作为c-Met酪氨酸激酶抑制剂的[1,2,4]三唑并[4,3-b]哒嗪化合物
CN115490708B (zh) 磺酰胺类大环衍生物及其制备方法和用途
RU2831159C2 (ru) N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2
RU2831159C9 (ru) N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2
HK40001439A (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40001439B (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40019323A (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40019323B (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
BR112019001666B1 (pt) Compostos de n-(fenilsulfonil)benzamidas e sais e solvatos dos mesmos, composições farmacêuticas e seus usos no tratamento de doenças, distúrbios ou afecções através da inibição de bcl-2
HK40001725A (en) N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors
HK40001725B (en) N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428